Investors

Tribute Pharmaceuticals News Archive

Date Title and Summary
Toggle Summary RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016
MILTON, ONTARIO -- (Marketwired) -- 12/29/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty    pharmaceutical company with a primary focus on the acquisition, licensing,    development and promotion
Toggle Summary Tribute Schedules Special Shareholder Meeting for February 1, 2016
    MILTON, ONTARIO -- (Marketwired) -- 12/28/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty    pharmaceutical company with a primary focus on the acquisition, licensing,    development and promotion of healthcare products in
Toggle Summary POZEN and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals
     -Canada Domicile Provides Similar Competitive    Structure and Benefits to Ireland-     -Previously Scheduled Shareholder Meetings of    POZEN and Tribute to be Rescheduled-     CHAPEL HILL, NORTH CAROLINA and MILTON, ONTARIO -- (Marketwired) -- 12/07/15 --    POZEN Inc.
Toggle Summary Tribute Announces Third Quarter 2015 Results
    Revenue Up 133%, EBITDA Up 281% Over    Comparative Period     MILTON, ONTARIO -- (Marketwired) -- 11/09/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a diversified    healthcare company with a primary focus on the acquisition,
Toggle Summary POZEN and Tribute Announce Effectiveness of Registration Statement on Form S-4
    POZEN Schedules Stockholder Meeting for December 10, 2015     Tribute Schedules Shareholder Meeting for December 9, 2015     CHAPEL HILL, N.C. & MILTON, Ontario--November 6, 2015--POZEN Inc. ("POZEN")    (POZN) and Tribute Pharmaceuticals Canada Inc.
Toggle Summary Tribute Comments on Trading Activity at the Request of IIROC
MILTON, ONTARIO -- (Marketwired) -- 09/29/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals Announces Second Quarter 2015 Results
Revenue Up 59%, Gross Profit Up 101% over Comparative Period MILTON, ONTARIO -- (Marketwired) -- 08/17/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing,
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela®, Proferrin® and 13 Additional Products MILTON, ONTARIO--(Marketwired - June 17, 2015) - NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela(R), Proferrin(R) and 13 Additional Products MILTON, ONTARIO -- (Marketwired) -- 06/17/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition,
Toggle Summary Pozen Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US $350 Million Capital Commitment from Deerfield-Led Syndicate toFund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian Adams Will Lead World-Class Management
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor®, Commercial Expansion into U.S. Market and Completion of $12 Million Equity Financing
- William Maichle Hired as President of U.S. Operations MILTON, ONTARIO--(Marketwired - May 21, 2015) - NOT FOR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor(R) and Commercial Expansion into U.S. Market
- William Maichle Hired as President of U.S. Operations MILTON, ONTARIO -- (Marketwired) -- 05/21/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF )(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing,
Toggle Summary Tribute Pharmaceuticals Announces First Quarter 2015 Results
Revenue Up 60%, EBITDA Up 116% Over Comparative Period MILTON, ONTARIO -- (Marketwired) -- 05/12/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development
Toggle Summary Tribute Pharmaceuticals Schedules First Quarter 2015 Financial Results Conference Call
MILTON, ONTARIO -- (Marketwired) -- 05/08/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Investor Conference
MILTON, ONTARIO -- (Marketwired) -- 04/27/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index
MILTON, ONTARIO -- (Marketwired) -- 04/15/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX )(OTCQX: TBUFF ) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and
Toggle Summary Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference
MILTON, ONTARIO -- (Marketwired) -- 04/02/15 -- Tribute Pharmaceuticals Canada Inc. ("Tribute" or the "Company") (TSX VENTURE:TRX) (OTCQX:TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Raises US$2.7 Million Through the Exercise of Warrants
MILTON, ONTARIO -- (Marketwired) -- 03/19/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results
4th Quarter Revenue Up 70.5% and EBITDA Up 217% Over Comparative Periods MILTON, ONTARIO -- (Marketwired) -- 03/03/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition,
Toggle Summary Tribute Pharmaceuticals Board Members and Management Exercise Series A Warrants
MILTON, ONTARIO -- (Marketwired) -- 03/02/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals Schedules Fourth Quarter and 2014 Year End Financial Results Conference Call
MILTON, ONTARIO -- (Marketwired) -- 02/26/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals Engages BND Projects Inc. as Investor Relations Service Provider and Grants Options to Certain Officers and Directors
MILTON, ONTARIO -- (Marketwired) -- 01/29/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth in Excess of 60% and Full Year Revenue Growth of Greater Than 20%
MILTON, ONTARIO -- (Marketwired) -- 01/27/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the

Copyright West LLC. Minimum 15 minutes delayed.